These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 35126388

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
    Pechtl IC, Kavanagh D, McIntosh N, Harris CL, Barlow PN.
    J Biol Chem; 2011 Apr 01; 286(13):11082-90. PubMed ID: 21270465
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Copy number variation analysis using next-generation sequencing identifies the CFHR3/CFHR1 deletion in atypical hemolytic uremic syndrome: a case report.
    Park J, Yhim HY, Kang KP, Bae TW, Cho YG.
    Hematology; 2022 Dec 01; 27(1):603-608. PubMed ID: 35617302
    [Abstract] [Full Text] [Related]

  • 26. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.
    Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP.
    Clin Exp Immunol; 2015 Aug 01; 181(2):306-13. PubMed ID: 25079699
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
    Dekkers G, Brouwer MC, Jeremiasse J, Kamp A, Biggs RM, van Mierlo G, Lauder S, Katti S, Kuijpers TW, Rispens T, Jongerius I.
    J Immunol; 2020 Oct 01; 205(7):1778-1786. PubMed ID: 32848031
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Novel homozygous CD46 variant with C-isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome.
    Schack VR, Herlin MK, Pedersen H, Jensen JMB, Faerch M, Bundgaard B, Jensen RK, Jensen UB, Christensen R, Andersen GR, Thiel S, Höllsberg P.
    Eur J Immunol; 2022 Oct 01; 52(10):1610-1619. PubMed ID: 35987516
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
    Martínez-Barricarte R, Heurich M, López-Perrote A, Tortajada A, Pinto S, López-Trascasa M, Sánchez-Corral P, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S.
    Mol Immunol; 2015 Aug 01; 66(2):263-73. PubMed ID: 25879158
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.